Wockhardt has taken a significant step in global pharmaceutical innovation by successfully filing a Marketing Authorisation Application (MAA) with the European Medicines Agency on January 5, 2026, for its novel antibiotic WCK 5222. The submission positions Wockhardt among a select group of companies developing advanced solutions to combat life-threatening drug-resistant infections.
The European Medicines Agency is responsible for the scientific evaluation of new medicines across 27 European Union member states along with three European Economic Area countries—Norway, Iceland, and Liechtenstein—covering a total of 30 countries. Approval under this framework would enable WCK 5222 to be marketed across a large and strategically important healthcare region.
WCK 5222 is a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g), designed specifically to treat resistant Gram-negative infections. These infections are among the most serious challenges in modern medicine due to rising antimicrobial resistance and limited effective treatment options. Recognising the unmet medical need, the EMA has already confirmed that WCK 5222 qualifies for Accelerated Assessment, a pathway that shortens the standard review timeline for medicines of major public health importance.
In parallel, the New Drug Application for WCK 5222 is under fast-track review by the US Food and Drug Administration, highlighting strong regulatory momentum across key global markets. Priority review status in both Europe and the United States underscores the urgency of making new and effective therapies available for patients suffering from multidrug-resistant bacterial infections.
Wockhardt has stated that, based on the comprehensive clinical and regulatory data submitted, it expects approval of WCK 5222 for the treatment of resistant Gram-negative infections across all countries under the EMA’s jurisdiction. If approved, the drug could play a crucial role in addressing severe hospital-acquired infections and improving patient outcomes in critical care settings.
Notably, WCK 5222 represents a landmark achievement for Indian pharmaceutical research. It is the first New Chemical Entity discovered and developed in India to be submitted for pan-European marketing authorisation.